Get started
Author

Helle Toldbod

Observed names: H Toldbod, H. E. Toldbod, H. Toldbod, Helle E. Toldbod, Helle Erbs Toldbod, Helle M Toldbod, Toldbod, H, Toldbod, Helle
Observed institutions: Karolinska University Hospital, Uppsala University Hospital, Lund University, Aarhus University, Aarhus University Hospital, Copenhagen University Hospital, Vejle Sygehus, Skåne University Hospital, University of Plymouth, Umeå University
OpenAlex ID: A5111717066
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
2012 · Francesco d'Amore, Thomas Relander, et al. · Journal of Clinical Oncology · 594
Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer
2007 · Anne B. Als, Lars Dyrskjøt, et al. · Clinical Cancer Research · 206
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
2018 · Mats Jerkeman, Christian Winther Eskelund, et al. · The Lancet Haematology · 155
Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts
2010 · Anne Sofie Brems-Eskildsen, Karsten Zieger, et al. · BMC Cancer · 67
PDF
Potent Influence of Bovine Serum Proteins in Experimental Dendritic Cell‐Based Vaccination Protocols
2003 · H. E. Toldbod, R. Agger, et al. · Scandinavian Journal of Immunology · 37
PDF
Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant
2018 · Francesco d'Amore, Sirpa Leppä, et al. · Blood · 28
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial
2025 · David J Lewis, David J Lewis, et al. · The Lancet · 25
Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich
2024 · David John Lewis, Mats Jerkeman, et al. · Blood · 23
Pixantrone beyond monotherapy: a review
2019 · Cristina Barrenetxea Lekue, Silvina Grasso Cicala, et al. · Annals of Hematology · 23
PDF
Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial
2016 · Mats Jerkeman, Martin Hutchings, et al. · Blood · 17
Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials
2018 · Bettina Altmann, Gerald Wulf, et al. · Blood · 16
First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy
2012 · Francesco d'Amore, Sirpa Leppä, et al. · Blood · 12
The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK, DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis
2017 · Martin Bjerregård Pedersen, Thomas Relander, et al. · Blood · 11
High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)
2011 · Francesco d'Amore, Thomas Relander, et al. · Blood · 10
First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,
2011 · Francesco d'Amore, Maria Gomes da Silva, et al. · Blood · 8
Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas
2014 · Francesco d'Amore, Judit Joergensen, et al. · Blood · 7
A Phase 1/2 Study of Pixantrone, Etoposide, Bendamustine And, in Cd20+ Tumors, Rituximab in Patients With Relapsed Aggressive B‐ or T‐cell Lymphomas—the P[r]eben Study
2017 · F. d'Amore, S. Leppä, et al. · Hematological Oncology · 5
PDF
Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial
2022 · Thomas Relander, Martin Bjerregård Pedersen, et al. · Blood · 4
Response at Interim Evaluation Predicts Survival after Autologous Stem Cell Transplantation in Nodal Peripheral T-Cell Lymphoma; A Nordic Lymphoma Group Study
2016 · Fredrik Ellin, Knut Liestøl, et al. · Blood · 2
Upfront Autologuos Stem Cell Transplantation in Peripheral T-cell Lymphoma (NLG-T-01)
2012 · D'Amore, Francesco Annibale, Relander, T, et al. · 2
High-dose chemotherapy and autologous stem cell transplantation in previously untreated peripheral T-cell lymphoma - final analysis of a large prospective multicenter study (NLG-T-01)
2012 · D'Amore, Francesco Annibale, Relander, T, et al. · 1
47 | Ibrutinib and Rituximab Is Superior to Immunochemotherapy in Previously Untreated Mantle Cell Lymphoma Despite Lower Rates of Mrd Negativity
2025 · D. Lewis, C. Burton, et al. · Hematological Oncology
PDF
Long‐term Follow‐up and Gene Expression Profiles Associated With Outcome in Patients With Relapsed Aggressive B‐ or T‐cell Lymphomas Treated in the Nordic P[r]eben Trial
2023 · T. Relander, S. Leivonen, et al. · Hematological Oncology
PDF
Final Analysis of a Nordic Lymphoma Group Phase Ib/iia Trial of Pixantrone, Etoposide, Bendamustine And, in Cd20‐positive Tumors, Rituximab in Relapsed Aggressive B‐ or T‐cell Lymphomas
2021 · F d'Amore, S Leppä, et al. · Hematological Oncology
PDF
Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study
2019 · Suvi-Katri Leivonen, Judit Jørgensen, et al. · Blood
Works count: 35
Citation count: 1,253
H-index: 12
I10-index: 14
Year
Topic
Type